PPT-ARVs

do not get rid of HIV from the body they stop the production of virus HIV IS A VIRUS HIV virus HIV virus DEFENCE CELL DEFENCE CELLS PROTECT US FROM DISEASES HIV virus DEFENCE CELL. S Abdool Karim. Director. : CAPRISA. Pro Vice-Chancellor (Research): University of KwaZulu-Natal. Professor in Clinical Epidemiology, Columbia University. Associate Member, . Ragon. Institute of MGH, MIT and Harvard. TRIPS Flexibilities and . Access to Medicines in . Lesotho – . a public health view. Presentation to Civil Society meeting. Maseru. 12 August 2014. No access to medicines?. Local (clinic) – ordering, staff, calculations, overuse. Module 11:. Family Planning and PMTCT Services for Adolescents. 1. Module 11 Learning Objectives. After completing this module, participants will be able to:. . List the risks of adolescent pregnancy. the Centers. for Disease Control and Prevention (CDC) under the terms of cooperative agreement #U2GGH000994. Its contents are solely the responsibility of the authors and do not necessarily represent the views of the U.S. Government.. Learning Objectives. Understand key counseling techniques. Learn and apply motivational interviewing tools to adherence counseling. Outline. Key Counseling Techniques . Therapeutic Alliance. Collaborative Health Education. Greg Perry. Melbourne – International AIDS Conference. July 2014. 1. The Future of HIV Treatment?. All people on treatment have access to the best possible regimens. Treatment side effects are minimal or non-existent. Generic. HIV . Drugs. on 90-90-90. Esteban Burrone. Medicines Patent Pool. . . Impact in terms of treatment affordability. Impact in making new treatments available faster. Impact in making needed new formulations. What the Primary Care Provider Should Know. Carolyn K. Burr, . EdD. , RN. Co-Clinical Director NY/NJ AETC LPS. Deputy Director . François-Xavier Bagnoud Center. December 17. th. , 2013. Support for this program is provided in part through an educational training grant from the New Jersey Department of Health (NJDOH), Division of HIV,STD and TB Services.. . The GFATM procurement cliff. Sharonann Lynch. HIV & TB Policy Advisor. MSF Access Campaign. 1. 2. UNAIDS 2018. “There . were no new significant commitments from donors in 2017. . . The recent rise in donor funding is not expected to continue. , . prodrug. of . temsavir. . (attachment inhibitor). AI438011 Study. TAF (TFV . prodrug. ). Study 292-0102. Study 299-0102. Doravirine (non nucleoside reverse transcriptase inhibitor). MK1439007 Study. Basic principles of DDIs with ARVs: an introduction David Back University of Liverpool DDIs : Are not going away! Ageing Population Polypharmacy Increased use of ‘Over the Counter ’ Online access to drugs , . prodrug. of . temsavir. . (. attachment inhibitor). AI438011 Study. TAF (TFV . prodrug. ). Study 292-0102. Study 299-0102. Doravirine (non nucleoside reverse transcriptase inhibitor). MK1439007 Study. Hall 11B, RAI Amsterdam. Uptake and Procurement of Optimal Formulations for Children. Nandita Sugandhi and Jennifer Cohn. Disclosure. Reference: . https://www.cgr.nl/CGR.nl/media/CGR.nl/Gedragscode/Format-of-disclosure-slide-for-speakers-at-refresher-training-meetings.pdf. Scientific Workshop. Improving patient care through better management of HIV Drug Drug Interactions: an interactive case workshop exploring key clinical challenges in both Sub-Saharan Africa and Europe.